Grifols (GRFS) Competitors $7.55 -0.20 (-2.58%) Closing price 04:00 PM EasternExtended Trading$7.72 +0.17 (+2.19%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVXShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Moderna Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Sarepta Therapeutics Vaxcyte Grifols (NASDAQ:GRFS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals & insiders have more ownership in GRFS or TEVA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer GRFS or TEVA? Teva Pharmaceutical Industries received 983 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformGrifolsOutperform Votes35056.09% Underperform Votes27443.91% Teva Pharmaceutical IndustriesOutperform Votes133367.87% Underperform Votes63132.13% Which has stronger earnings & valuation, GRFS or TEVA? Grifols has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.21B0.72$64.20M$1.176.45Teva Pharmaceutical Industries$16.54B1.08-$1.64B-$1.45-10.83 Is GRFS or TEVA more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Teva Pharmaceutical Industries -9.91%42.46%6.65% Does the media refer more to GRFS or TEVA? In the previous week, Teva Pharmaceutical Industries had 23 more articles in the media than Grifols. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 1 mentions for Grifols. Teva Pharmaceutical Industries' average media sentiment score of 0.73 beat Grifols' score of 0.55 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Overall Sentiment Grifols Positive Teva Pharmaceutical Industries Positive Is GRFS or TEVA a better dividend stock? Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 4.8%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 6.4%. Grifols pays out 30.8% of its earnings in the form of a dividend. Teva Pharmaceutical Industries pays out -69.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. Do analysts prefer GRFS or TEVA? Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 49.13%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more risk and volatility, GRFS or TEVA? Grifols has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. SummaryTeva Pharmaceutical Industries beats Grifols on 15 of the 21 factors compared between the two stocks. Remove Ads Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.19B$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio6.457.2324.5519.25Price / Sales0.72230.77395.7294.09Price / Cash9.5465.6738.1634.64Price / Book0.606.617.064.46Net Income$64.20M$142.13M$3.19B$247.07M7 Day Performance-6.79%2.79%1.49%3.05%1 Month Performance2.30%2.70%5.87%-2.85%1 Year Performance18.71%-4.42%14.94%4.63% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols2.9826 of 5 stars$7.55-2.6%N/A+24.6%$5.19B$7.21B6.4526,300TEVATeva Pharmaceutical Industries2.605 of 5 stars$16.74+2.5%$23.43+40.0%+16.5%$18.97B$16.54B-11.5436,800SMMTSummit Therapeutics2.3689 of 5 stars$20.13-3.2%$34.11+69.5%+513.9%$14.85B$700,000.00-71.89110ITCIIntra-Cellular Therapies3.6015 of 5 stars$131.45+0.1%$106.08-19.3%+90.8%$13.98B$680.50M-151.09560Positive NewsGMABGenmab A/S4.1658 of 5 stars$20.80+1.4%$41.33+98.7%-35.5%$13.76B$21.53B11.952,204MRNAModerna4.102 of 5 stars$34.71+0.3%$59.60+71.7%-67.6%$13.39B$3.20B-3.743,900VTRSViatris1.9798 of 5 stars$9.25+1.6%$10.50+13.5%-21.5%$11.04B$14.74B-12.5037,000RDYDr. Reddy's Laboratories2.9487 of 5 stars$13.23+4.3%$17.00+28.5%-6.7%$11.04B$311.31B21.0624,800Gap UpASNDAscendis Pharma A/S3.0809 of 5 stars$168.84+10.4%$202.36+19.9%+15.8%$10.25B$363.64M-23.781,017News CoveragePositive NewsGap UpHigh Trading VolumeSRPTSarepta Therapeutics4.5729 of 5 stars$101.35+4.3%$170.41+68.1%-40.2%$9.83B$1.90B81.081,314PCVXVaxcyte2.3362 of 5 stars$75.23+1.2%$147.50+96.1%+9.8%$9.69BN/A-16.35160Positive News Remove Ads Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives MRNA Alternatives VTRS Alternatives RDY Alternatives ASND Alternatives SRPT Alternatives PCVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRFS Stock Free GRFS Stock Alerts